Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin. Prognosis is poor, with limited treatment options available, and the median survival remains just 3–5 years. Despite the use of pirfenidone and nintedanib for the treatment of IPF, curative therapies rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzouvelekis, Argyrios, Toonkel, Rebecca, Karampitsakos, Theodoros, Medapalli, Kantha, Ninou, Ioanna, Aidinis, Vasilis, Bouros, Demosthenes, Glassberg, Marilyn K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962715/
https://www.ncbi.nlm.nih.gov/pubmed/29868594
http://dx.doi.org/10.3389/fmed.2018.00142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962715/
https://www.ncbi.nlm.nih.gov/pubmed/29868594
http://dx.doi.org/10.3389/fmed.2018.00142

Ejemplares similares